Relmada Therapeutics, Inc.
RLMD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001553643
In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Relmada Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 50 | 44 | −6 |
| Shares | 5.30M | 7.74M | +2.44M (+45.9%) |
| Value | $3.18M | $15.5M | +$12.4M (+389.1%) |
New holders (2)
Institutions that held Relmada Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Boothbay Fund Management, LLC | 693,236 | $1.39M | 0.04% |
| Farther Finance Advisors, LLC | 838 | $1.68K | 0.00% |
Sold out (8)
Institutions that held Relmada Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| ADAR1 Capital Management, LLC | 130,000 | $78.0K |
| XTX Topco Ltd | 46,039 | $27.6K |
| Wealthedge Investment Advisors, LLC | 28,000 | $16.8K |
| Group One Trading, L.P. | 26,301 | $15.8K |
| Ground Swell Capital, LLC | 15,320 | $9.20K |
| HRT Financial LP | 12,162 | $7.00K |
| JPMorgan Chase & Co | 5,103 | $3.06K |
| Raymond James Financial Inc | 587 | $352 |